Cellipont and CellVax Expand Cell-Therapy Partnership to Advance Autologous Therapies

Cellipont Bioservices and CellVax Therapeutics Expand Partnership to Advance cGMP Manufacturing of Personalized Immunotherapy FK-GI101 for GI Cancers

THE WOODLANDS, Texas and MIAMI, July 29, 2025 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO) and CellVax Therapeutics Inc., a privately held clinical-stage biotechnology company focused on individualized cell-based immunotherapies, today announced a partnership expansion upon prior work on FK-PC101 - currently in a Phase II clinical trial for high-risk prostate cancer pati…

Cellipont and CellVax expand cell-therapy partnership to advance autologous therapies

The companies will collaborate to manufacture two pipeline cancer treatments.